NEW YORK (MainStreet) — Medical marijuana stocks have been all the rage, and though CARA has been lumped into that category, the story is much deeper. Dr. Derek Chalmer, CEO of Cara Therapeutics, joins Jill Malandrino at the NASDAQ MarketSite to give a complete review of the company. The company's lead program is an opiate-based initiative with the promise of analgesia with no narcotic side-effects. CARA's main focus is obtaining approval for the first medications for 2016.